$22.84
5.85% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Cidara Therapeutics, Inc. Stock price

$22.84
+3.48 17.98% 1M
-0.04 0.17% 6M
-4.04 15.03% YTD
+8.68 61.30% 1Y
-53.36 70.03% 5Y
-289.56 92.69% 10Y
-297.16 92.86% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-1.42 5.85%
ISIN
US1717571079
Symbol
CDTX
Sector
Industry

Key metrics

Market capitalization $296.23m
Enterprise Value $128.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 426.94
P/S ratio (TTM) P/S ratio 987.44
P/B ratio (TTM) P/B ratio 1.97
Revenue growth (TTM) Revenue growth -99.35%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-192.83m
Free Cash Flow (TTM) Free Cash Flow $-191.95m
Cash position $168.15m
EPS (TTM) EPS $-12.90
P/E forward negative
Short interest 3.66%
Show more

Is Cidara Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Cidara Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cidara Therapeutics, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Cidara Therapeutics, Inc. forecast:

Buy
100%

Financial data from Cidara Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.30 0.30
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
16% 16%
7,733%
- Research and Development Expense 91 91
47% 47%
30,187%
-193 -193
407% 407%
-64,200%
- Depreciation and Amortization 0.23 0.23
64% 64%
77%
EBIT (Operating Income) EBIT -193 -193
405% 405%
-64,276%
Net Profit -183 -183
402% 402%
-60,993%

In millions USD.

Don't miss a Thing! We will send you all news about Cidara Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cidara Therapeutics, Inc. Stock News

Positive
Seeking Alpha
20 days ago
Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients. Readout of a randomized ph2b trial of CD388 is expected ...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here.
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare Conference Date: Wednesday, May 21, 2025 Time: 10:00 AM ET Event: Jefferie...
More Cidara Therapeutics, Inc. News

Company Profile

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Jeffrey Stein
Employees 38
Founded 2012
Website www.cidara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today